Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial
| Autor: | Somaia Mokbel, Shaymaa M. Deifalla, Sahar M A Hassanein, M. El-Houssinie |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pediatrics medicine.medical_specialty medicine.medical_treatment nootropic factor cerebrolysin Body weight Placebo group communication defects 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine perinatal brain insult medicine Stroke Saline Communication defects Communication and Symbolic-Behavior-Scale-Developmental Profile medicine.disease infant Clinical trial 030104 developmental biology Neurology chemistry Anesthesia Cerebrolysin Original Article Neurology (clinical) Psychology symbolic speech development 030217 neurology & neurosurgery |
| Zdroj: | Journal of Clinical Neurology (Seoul, Korea) |
| ISSN: | 2005-5013 1738-6586 |
| Popis: | Background and Purpose The neuroregenerative drug Cerebrolysin has demonstrated efficacy in improving cognition in adults with stroke and Alzheimer's disease. The aim of this study was to determine the efficacy and safety of Cerebrolysin in the treatment of communication defects in infants with severe perinatal brain insult. Methods A randomized placebo-controlled clinical trial was conducted in which 158 infants (age 6-21 months) with communication defects due to severe perinatal brain insult were enrolled; 120 infants completed the study. The Cerebrolysin group (n=60) received twice-weekly Cerebrolysin injections of 0.1 mL/kg body weight for 5 weeks (total of ten injections). The placebo group (n=60) received the same amount and number of normal saline injections. Results The baseline Communication and Symbolic-Behavior-Scale-Developmental Profile scores were comparable between the two groups. After 3 months, the placebo group exhibited improvements in the social (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|